Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $65.00. Designed for personal research, portfolio monitoring, and AI-assisted ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
EVEREST MED (01952.HK) announced that its wholly owned subsidiary, Everest Medicines (Singapore) Pte. Ltd., as licensor, has ...
Today’s analyst ratings show a mixed but still broadly constructive market tone, with increasing dispersion in conviction. Analysts continue to support lon ...
Investor's Business Daily on MSN
Stock market today: Dow ends higher on Iran deal hopes; SpaceX rockets 19% in debut
Stock Market Today: The Dow Jones index rises Friday on U.S.-Iran peace deal hopes. SpaceX stock jumps on its debut.
Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results